Oncology

Back to articles

Nivolumab: An emerging option for advanced melanoma

KEY POINT

In previously untreated patients with advanced melanoma without a BRAF mutation, use of nivolumab (Opdivo—Bristol–Myers Squibb) was associated with increased overall survival and progression-free survival compared with dacarbazine (DTIC–Dome—Bayer), according to a recent trial published in the New England Journal of Medicine.

SOURCES

Robert C et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.

Sznol M et al. Release the hounds! Activating the T-cell response to cancer [Editorial]. N Engl J Med. 2015;372:374–5.